---
document_datetime: 2024-02-19 11:44:50
document_pages: 24
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lonquex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lonquex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 12.9884278
conversion_datetime: 2025-12-28 18:56:59.907296
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lonquex

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0088/G            | This was an application for a group of variations. | 05/01/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0087 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                | 21/11/2023 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0086   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                     | 08/11/2023 |     | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0080   | Update of section 4.4 of the SmPC in order to add a class-effect warning risk of Acute Myeloid Leukaemia and Myelodysplastic Syndrome in breast and lung cancer patients in conjunction with chemotherapy and/or radiotherapy based on the cumulative review of literature and MAH safety database. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/10/2023 |     | SmPC and PL     | Based on cumulative review of literature an MAH's safety database, the increased risk of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) in breast and lung cancer patients receiving lipegfilgrastim treatment in conjunction with chemotherapy and/or radiotherapy was assessed. In an observational post-marketing study, MDS and AML were associated with the use of pegfilgrastim, another granulocyte colony-stimulating factor (G-CSF), in combination with chemotherapy and/or radiotherapy in breast and lung cancer patients. A similar association is not known between lipegfilgrastim and MDS/AML. Nevertheless, patients with breast cancer and patients with lung cancer should be monitored for signs and symptoms of MDS/AML. For more information, please refer to the Summary of |
| IAIN/0085 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                | 26/09/2023 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0084   | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                          | 12/09/2023   | n/a   |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| IB/0082/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product | 06/07/2023   |       | SmPC and PL |
| IA/0083   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                             | 05/07/2023   | n/a   |             |
| IB/0079   | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                                                                                                                | 04/07/2023   | n/a   |             |
| IAIN/0081 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                              | 12/06/2023   | n/a   |             |
| IB/0078/G | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                      | 12/05/2023   | n/a   |             |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                    |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0077    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                    | 23/02/2023 | 19/04/2023 | SmPC                   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lonquex in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. The Product Information was updated combining the two separate SmPCs for the PFS and vial presentations and is also brought in line with the latest QRD template. |
| IB/0076   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                        | 16/12/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0074/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 31/10/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IAIN/0075 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                         | 17/10/2022 | 19/04/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0073   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                            | 05/10/2022   | n/a        |                        |                                                                                                                                                                                                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0072/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                           | 23/08/2022   | n/a        |                        |                                                                                                                                                                                                                                                      |
| IB/0071   | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/07/2022   | n/a        |                        |                                                                                                                                                                                                                                                      |
| II/0058/G | This was an application for a group of variations. Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age appropriate presentation in vials; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC were updated. The Package Leaflet was updated in accordance. Version 14.1 of the RMP has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the | 23/06/2022   | 22/07/2022 | SmPC, Labelling and PL | The variation application concerned the extension of indication to paediatric patients (2 years of age and older) and introduction of an age-appropriate presentation in vials. Please refer to Scientific Discussion 'Lonquex-H-C-2556-II- 0058/G'. |

<div style=\"page-break-after: always\"></div>

|                     | Package Leaflet. Furthermore, the PI was brought in line with the latest QRD template version 10.2. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                        |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0070             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                    | 28/03/2022 | n/a        |                        |                                   |
| PSUSA/10111 /202107 | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                                       | 10/03/2022 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0069             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                 | 17/12/2021 | 14/01/2022 | SmPC, Labelling and PL |                                   |
| II/0066             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                          | 28/10/2021 | n/a        |                        |                                   |
| IB/0067             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other                                                                                                                                                                                                                                                                                                                                   | 27/10/2021 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                              |            |            |                 |                     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------|
| IA/0065   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                    | 12/07/2021 | n/a        |                 |                     |
| II/0064/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a    | 08/07/2021 | 14/01/2022 | Annex II and PL | biol/immunol method |
| IB/0063   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                       | 30/04/2021 | n/a        |                 |                     |
| II/0062   | Submission of the final report from study XM22- ONC-5002 listed as a category 3 study in the RMP. This is a drug utilisation study on the prescribing patterns of lipegfilgrastim in the EU. The RMP version 13.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission competent authority | 11/03/2021 | n/a        |                 | of studies to the   |

<div style=\"page-break-after: always\"></div>

| II/0060   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/01/2021   | 14/01/2022   | Annex II   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|
| IB/0059/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 18/11/2020   | n/a          |            |
| IB/0061   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/11/2020   | n/a          |            |
| IB/0057/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/07/2020   | n/a          |            |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                  |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0056   | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                    | 24/06/2020 | n/a |
| IA/0055   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                               | 29/05/2020 | n/a |
| IB/0054/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 12/05/2020 | n/a |
| II/0053/G | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol                                                                           | 12/09/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | product and any of the test methods at the site is a biol/immunol method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                           |            |            |                       |                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0048             | Update of section 5.1 of the SmPC based on results from study XM22-ONC-40041 listed as an imposed PASS in the Annex II; this is a multinational, multicentre, randomised, double-blind, placebo- and active-controlled study to further investigate the risks of disease progression and mortality associated with lipegfilgrastim. The Annex II and Package Leaflet are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/07/2019 | 13/07/2020 | SmPC, Annex II and PL | A post-authorisation safety study XM22-ONC-40041 was conducted to collect data of disease progression and mortality in patients with advanced squamous or non- squamous cell lung cancer receiving lipegfilgrastim in addition to the platinum-based chemotherapy. Increased risk of disease progression or death was not observed with lipegfilgrastim. |
| IB/0052             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                      | 14/05/2019 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/10111 /201807 | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28/02/2019 | 26/04/2019 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10111/201807.                                                                                                                                                                                                               |
| IA/0051/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                           | 18/04/2019 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                     |            |            |                        |                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------|
| IB/0050   | C.I.z - Changes (Safety/Efficacy) of Human and Products - Other variation                                                                                                                                                                                                                                                  | 18/02/2019 | 26/04/2019 | SmPC and PL            | Veterinary Medicinal |
| IB/0049   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                | 15/02/2019 | n/a        |                        |                      |
| T/0046    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                        | 13/12/2018 | 21/01/2019 | SmPC, Labelling and PL |                      |
| IA/0047/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 12/12/2018 | n/a        |                        |                      |
| IB/0044   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                             | 24/10/2018 | 21/01/2019 | SmPC and PL            |                      |
| II/0041/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The                                                                                                                                                                | 13/09/2018 | n/a        |                        |                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| change relates to a biological material [-] used in the biological/immunological B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.j - Change in the starting material/reagent/intermediate Replacement or addition control/testing takes place method at the site is a B.I.a.1.k - Change in the starting material/reagent/intermediate storage site of MCB and/or B.I.a.1.k - Change in the starting material/reagent/intermediate storage site of MCB and/or B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a   |            |            |                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0043 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/07/2018 | 21/01/2019 | Annex II and PL |
| IB/0042   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/07/2018 | n/a        |                 |

<div style=\"page-break-after: always\"></div>

| IB/0040   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   | 15/05/2018   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0039    | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 22/02/2018   | 08/05/2018 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lonquex in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: The currently ongoing imposed post-authorisation safety study XM22-ONC-40041 to further investigate the risks of disease progression and mortality associated with Lonquex in patients with malignancy treated with cytotoxic chemotherapy is key to the benefit-risk profile of the product. The final report for this study is due in December 2018. Therefore, based upon the safety profile of Lonquex, which requires the submission of yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years' time. In addition, sections 4.4 and 4.8 of the SmPC were updated to mention that events of glomerulonephritis have been reported in patients receiving filgrastim or pegfilgrastim and that these events generally, resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim. Urinalysis monitoring is recommended. The package leaflet has been amended accordingly. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10111 /201707   | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                                                                        | 08/02/2018   | n/a        |                 | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------|
| IB/0035               | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                               | 04/10/2017   | n/a        |                 |                                     |
| IA/0036               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                        | 13/09/2017   | 08/05/2018 | Annex II and PL |                                     |
| IAIN/0037             | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                            | 07/09/2017   | 08/05/2018 | Annex II and PL |                                     |
| IA/0034/G             | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits | 10/08/2017   | n/a        |                 |                                     |
| IB/0033               | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                  | 16/05/2017   | n/a        |                 |                                     |

<div style=\"page-break-after: always\"></div>

| II/0030/G           | This was an application for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                   | 16/03/2017   | n/a   |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0032             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                              | 13/03/2017   | n/a   |                                   |
| PSUSA/10111 /201607 | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                        | 09/02/2017   | n/a   | PRAC Recommendation - maintenance |
| II/0027             | B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol                                                                                                                                                                                                     | 15/09/2016   | n/a   |                                   |
| II/0025/G           | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release | 15/09/2016   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure   |            |            |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10111 /201601 | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 02/09/2016 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0028/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/07/2016 | 20/04/2017 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                          | 26/05/2016 | 20/04/2017 | SmPC, Labelling and PL | Generally asymptomatic cases of splenomegaly have been reported after administration of lipegfilgrastim and infrequent cases of splenic rupture, including fatal cases, have been reported after administration of G CSF or derivatives. Spleen size should therefore be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in patients reporting left upper abdominal pain or shoulder tip pain. |
| IB/0026/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 24/05/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0022   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting                                                                                                                                                                                                                                                                                                                     | 25/02/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10111 /201507 | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                    | 11/02/2016 | n/a | PRAC Recommendation - maintenance |
| IB/0021             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                              | 04/12/2015 | n/a |                                   |
| IB/0019             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                       | 17/09/2015 | n/a |                                   |
| IB/0018             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                       | 17/09/2015 | n/a |                                   |
| PSUSA/10111 /201501 | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                    | 10/09/2015 | n/a | PRAC Recommendation - maintenance |
| IB/0017/G           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement | 22/07/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------|
| IB/0014   | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                         | 16/06/2015 | 02/06/2016 | SmPC and PL |                         |
| IA/0015/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished non-significant in-process test | 22/05/2015 | n/a        |             | product - Deletion of a |
| IB/0016   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                            | 21/05/2015 | n/a        |             |                         |
| IB/0011   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                      | 13/05/2015 | n/a        |             |                         |
| IB/0012   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                      | 20/03/2015 | 28/05/2015 | Annex II    |                         |

<div style=\"page-break-after: always\"></div>

| PSUSA/10111 /201407   | Periodic Safety Update EU Single assessment - lipegfilgrastim                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/02/2015   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                     |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0010/G           | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                      | 10/02/2015   | 28/05/2015 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                       |
| IB/0009/G             | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 02/12/2014   | n/a        |                        |                                                                                                                                                                                                                                                                                       |
| II/0004               | Update of the product information in order to include information regarding capillary leakage syndrome (CLS); a class effect of granulocyte-colony stimulating factors (G-CSFs).                                                                                                                                                                                                                                                                                                                             | 20/11/2014   | 28/05/2015 | SmPC, Annex II and PL  | Following the review of potential signals of capillary leak syndrome (CLS) and cytokine release syndrome in association with filgrastim and pegfilgrastim, the PRAC recommended that the product information for all G-CSFs be updated to include the undesirable effect of capillary |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                      |            |     | leak syndrome. Consequently, the MAH has submitted a variation to update SmPC and PIL for lipegfilgrastim to include warnings and information on CLS. Sections 4.4 and 4.8 of the SmPC have been updated to include that CLS, which can be life threatening if treatment is delayed, has been reported mostly in cancer patients undergoing chemotherapy after administration of G-CSF or derivatives. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0008   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                           | 14/11/2014 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0006/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 30/09/2014 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUV/0002 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                 | 11/09/2014 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0005/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/08/2014   | n/a        |                 |                     |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|---------------------|
| IAIN/0003/G   | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.7 - Administrative change - Deletion of | 20/06/2014   | 28/05/2015 | Annex II and PL | manufacturing sites |

<div style=\"page-break-after: always\"></div>

| T/0001   | Transfer of Marketing Authorisation from Teva Pharma B. V. to UAB 'Sicor Biotech'.   | 27/03/2014   | 10/04/2014   | SmPC, PL      |
|----------|--------------------------------------------------------------------------------------|--------------|--------------|---------------|
|          |                                                                                      |              |              | Labelling and |
|          | Transfer of Marketing Authorisation                                                  |              |              |               |